Medicinova Inc insider trading
Every open-market purchase and sale by Medicinova Inc's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Medicinova Inc’s insiders pay?
From May 30, 2012 to September 29, 2026, 7 insiders reported 13 open-market purchases and 6 sales not made under a pre-set plan in Medicinova Inc. Twelve months after each purchase was reported, the shares were +19.7% against the S&P 500 on average (median +18.2%), over 4 purchases with a full year of prices; 50% beat the index. After sales, the shares moved −70.7% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on September 12, 2016 into $19,457 by November 2, 2026, +6.8% a year. It held shares 19% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $17,416 (+5.6% a year), and held throughout $41,152 (+15.0%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Kobayashi Yutaka | Director | 8 | −0.9% (3) | 33% | 0 | — | May 15, 2017 |
| Izumi Tatsuo | Director | 2 | — | — | 1 | — | December 13, 2013 |
| Nagao Hideki | Director | 0 | — | — | 3 | −70.7% (1) | November 30, 2022 |
| Ishizaka Yoshio | Director | 2 | +81.5% (1) | 100% | 0 | — | August 23, 2017 |
| 3d Opportunity Master Fund | Other | 0 | — | — | 1 | — | September 29, 2026 |
| Iwaki Yuichi | President and CEO | 1 | — | — | 0 | — | March 12, 2020 |
| Morris Arlene | Director | 0 | — | — | 1 | — | May 23, 2013 |